(Q28175811)

https://api.crossref.org/works/10.1038/SJ.JHH.1001880

Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.JHH.1001880

Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.JHH.1001880

Cyclooxygenase inhibitors: drugs for cancer prevention

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.JHH.1001880

Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.JHH.1001880

Potential adverse interaction between aspirin and Lisinopril in hypertensive rats

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.JHH.1001880

Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.JHH.1001880

Role of cyclooxygenase products in the regulation of vascular tone and in the endothelial vasodilator function of normal, hypertensive, and hypercholesterolemic humans

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.JHH.1001880

Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils

21 April 2017

1 reference

https://api.crossref.org/works/10.1038/SJ.JHH.1001880

The prothrombotic state in hypertension and the effects of antihypertensive treatment

21 April 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Endothelial dysfunction: methods of assessment and application to hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Thrombogenesis, atherogenesis and angiogenesis in vascular disease: a new 'vascular triad'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Antihypertensive therapy and endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Antithrombotic therapy in hypertension: a Cochrane Systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Aspirin protects endothelial cells from oxidative stress--possible synergism with vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Aspirin protects low density lipoprotein from oxidative modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Aspirin improves endothelial dysfunction in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Statins: the new aspirin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Effects of cyclooxygenase inhibition on endothelial function in hypertensive patients treated with angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880

inferred from DOI database lookup

7 January 2021

based on heuristic

Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001880